SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter R. Little, Vickie L. King, Kylie R. Davis, Sallie B. Cosgrove, Michael R. Stegemann, A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs, Veterinary Dermatology, 2015, 26, 1
  2. 2
    Pedro J. Ginel, Eduardo Hernández, Rosario Lucena, Beatriz Blanco, Manuel Novales, Elena Mozos, Allergen-specific immunotherapy in horses with insect bite hypersensitivity: a double-blind, randomized, placebo-controlled study, Veterinary Dermatology, 2014, 25, 1
  3. 3
    P. Forsythe, S. Paterson, Ciclosporin 10 years on: indications and efficacy, Veterinary Record, 2014, 174, Suppl_2, 13

    CrossRef

  4. 4
    Ashley N. Stich, Wayne S. Rosenkrantz, Craig E. Griffin, Clinical efficacy of low-level laser therapy on localized canine atopic dermatitis severity score and localized pruritic visual analog score in pedal pruritus due to canine atopic dermatitis, Veterinary Dermatology, 2014, 25, 5
  5. 5
    Caroline Gadeyne, Peter Little, Vickie L. King, Nigel Edwards, Kylie Davis, Michael R. Stegemann, Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia, Veterinary Dermatology, 2014, 25, 6
  6. 6
    T. Nuttall, D. Reece, E. Roberts, Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis, Veterinary Record, 2014, 174, Suppl_2, 3

    CrossRef

  7. 7
    Ilaria Marech, Rosa Patruno, Nicola Zizzo, Claudia Gadaleta, Marcello Introna, Alfredo Francesco Zito, Cosmo Damiano Gadaleta, Girolamo Ranieri, Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?, Critical Reviews in Oncology/Hematology, 2014, 91, 1, 98

    CrossRef

  8. 8
    J. Schumann, S. Basiouni, T. Gück, H. Fuhrmann, Treating canine atopic dermatitis with unsaturated fatty acids: the role of mast cells and potential mechanisms of action, Journal of Animal Physiology and Animal Nutrition, 2014, 98, 6
  9. 9
    Sallie B. Cosgrove, Jody A. Wren, Dawn M. Cleaver, Kelly F. Walsh, Stacey I. Follis, Vickie I. King, Jezaniah-Kira S. Tena, Michael R. Stegemann, A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis, Veterinary Dermatology, 2013, 24, 6
  10. 10
    Sallie B. Cosgrove, Jody A. Wren, Dawn M. Cleaver, David D. Martin, Kelly F. Walsh, Jessica A. Harfst, Stacey L. Follis, Vickie L. King, Joseph F. Boucher, Michael R. Stegemann, Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis, Veterinary Dermatology, 2013, 24, 5